Document Detail

Small for gestational age and magnesium in cord blood platelets: intrauterine magnesium deficiency may induce metabolic syndrome in later life.
Jump to Full Text
MedLine Citation:
PMID:  21490788     Owner:  NLM     Status:  MEDLINE    
Magnesium deficiency in pregnancy frequently occurs because of inadequate or low intake of magnesium. Magnesium deficiency during pregnancy can induce not only maternal and fetal nutritional problems, but also consequences that might last in offspring throughout life. Many epidemiological studies have disclosed that small for gestational age (SGA) is associated with an increased risk of insulin resistance in adult life. We reported that intracellular magnesium of cord blood platelets is lower in SGA groups than that in appropriate for gestational age groups, suggesting that intrauterine magnesium deficiency may result in SGA. Taken together, intrauterine magnesium deficiency in the fetus may lead to or at least program insulin resistance after birth. In this review, we propose that intrauterine magnesium deficiency may induce metabolic syndrome in later life. We discuss the potential contribution of aberrant magnesium regulation to SGA and to the pathogenesis of metabolic syndrome.
Junji Takaya; Kazunari Kaneko
Related Documents :
21431328 - Role of fetal abdominal circumference as a prognostic parameter of perinatal complicati...
21373848 - Cytoskeletal remodelling proteins identified in fetal-maternal interface in pregnant wo...
21253228 - Common physical discomforts of pregnancy.
8671348 - Calcitonin gene-related peptide reverses the hypertension and significantly decreases t...
25301428 - Isaacs' syndrome in pregnancy.
2787278 - Development of percutaneous intramuscular electrode for multichannel fes system.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-12-28
Journal Detail:
Title:  Journal of pregnancy     Volume:  2011     ISSN:  2090-2735     ISO Abbreviation:  J Pregnancy     Publication Date:  2011  
Date Detail:
Created Date:  2011-04-14     Completed Date:  2013-05-22     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  101553823     Medline TA:  J Pregnancy     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  270474     Citation Subset:  IM    
Department of Pediatrics, Kansai Medical University, 10-15 Fumizonocho, Moriguchi, Osaka 570-8506, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Platelets / metabolism
Fetal Blood
Infant, Newborn
Infant, Small for Gestational Age / blood*
Magnesium / blood
Magnesium Deficiency / blood,  complications*
Metabolic Syndrome X / etiology*
Pregnancy Complications / blood*
Prenatal Exposure Delayed Effects
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): J Pregnancy
Journal ID (publisher-id): JP
ISSN: 2090-2727
ISSN: 2090-2735
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2011 J. Takaya and K. Kaneko.
Received Day: 6 Month: 10 Year: 2010
Accepted Day: 30 Month: 11 Year: 2010
Print publication date: Year: 2011
Electronic publication date: Day: 28 Month: 12 Year: 2010
Volume: 2011E-location ID: 270474
ID: 3066640
PubMed Id: 21490788
DOI: 10.1155/2011/270474

Small for Gestational Age and Magnesium in Cord Blood Platelets: Intrauterine Magnesium Deficiency May Induce Metabolic Syndrome in Later Life
Junji TakayaI1*
Kazunari KanekoI1
Department of Pediatrics, Kansai Medical University, 10-15 Fumizonocho, Moriguchi, Osaka 570-8506, Japan
Correspondence: *Junji Takaya:
[other] Academic Editor: R. L. Deter

1. Introduction

Magnesium (Mg) is an important cofactor for the enzymes that are involved in carbohydrate metabolism: an important role of Mg in insulin action has been reported [1, 2]; low serum and intracellular Mg ([Mg2+]i) concentrations are associated with insulin resistance, impaired glucose tolerance, and decreased insulin secretion [3, 4]. Furthermore, lower dietary Mg intake could cause insulin resistance both in children and adults [5, 6]. Based on these findings, we studied whether low [Mg2+]i in the fetus would be one of the critical abnormalities associated with small for gestational age (SGA).

In addition, several studies have shown the association of size at birth or indices in poor fetal growth with later development of metabolic syndrome and insulin resistance [7]. Hales et al. proposed that impaired glucose tolerance and type 2 diabetes might arise as a result of programming [8]. Programming is a term used to describe persistent changes in organ structure and function caused by exposure to adverse environmental influences during critical periods of development [9]. These findings have led to the “fetal origin” hypothesis, which proposes that fetal adaptation to an adverse intrauterine environment affecting fetal growth may program life-long physiological changes [10]. It has been proposed that various fetal growth patterns and intrauterine growth retardation (IUGR) arise as a result of an early stimulus or insult. Since both fetal weight and length gains are closely related, there is much overlap between SGA and IUGR. We focus on intrauterine undernutrition and SGA. SGA is defined as birth weight and/or length at least 2 standard deviations below the mean for gestational age.

In this review, we discuss the potential contribution of aberrant Mg regulation to SGA and to the pathogenesis of metabolic syndrome later in life.

2. Magnesium Deficiency During Pregnancy

It is reported that the amount of maternal Mg intake is not only associated with pregnancy outcome but also with infant outcome [11]. The mean daily intake of Mg (284.3 mg/day) during pregnancy was found to be lower than recommended [12]. For example, Mg deficiency is reported to occur in 44% of pregnant Indian women [13]. Another study has demonstrated that mothers who drink water containing high amounts of Mg have a reduced risk of having very low birth weight infants (less than 1,500 g of birth weight) [14]. By the end of a normal pregnancy, the fetus is believed to have acquired approximately 28 g of calcium, 16 g of phosphorous, and 0.7 g of Mg, mostly during the third trimester, also the time when 80% of fetal accretion of Mg occurs [15].

The fetal circulation contains higher levels of total calcium, ionized calcium, and Mg compared to maternal blood [16]. In the placental membrane, copper and selenium share the same transport pathway along a concentration gradient in the maternal-fetal direction, while Mg and iron use predominantly an active transport pathway [17]. In fact, evidence for an active transport mechanism for Mg in the placenta has been demonstrated in cultured trophoblast cells in which low [Mg2+]i is maintained by the function of a Na+/Mg2+ exchanger [18]. Mg levels in umbilical cord blood are the lowest in preterm low birth weight babies, followed by term low birth weight babies and are the highest in term controls (P < .05) [19].

Calcium and Mg have an immediate effect on placental vascular flow. Reduced placental vascular flow is at least, in part, responsible for placental insufficiency and fetal growth retardation (FGR). Calcium and Mg are cofactors of a variety of enzymes. A variety of hormones, cytokines, and growth factors produced by fetal membranes and the placenta can act locally on the myometrium [20]. The ability of the uterine artery to dilate during pregnancy may be specifically related to the upregulation of multiple pathways for the production of nitric oxide [21]. The activity of constitutive nitric oxide synthase is dependent on calcium and is inhibited by a reduction in the concentration of Mg [22].

Blood Mg levels were reportedly lower in women with severe pre-eclampsia than in healthy pregnant women (1.63 ± 0.05 mg/dL versus 1.87 ± 0.05 mg/dL; P < .001) [23]. Mg is widely used in obstetric practice to treat pre-eclampsia. Therapeutic levels of Mg have also been found to produce specific placental effects such as vasodilation [24]. From an in vitro study of human umbilical artery resistance [25], Mg sulfate was found to exert a relaxant effect on umbilical arterial tone attenuating the vasoconstrictor effect of angiotensin II and endothelin-1 in the fetal-placental vasculature. Mg sulfate used for the treatment of pre-eclampsia or hypertensive disease in pregnancy may have beneficial effects on the fetoplacental circulation. Prenatal treatment with Mg sulfate may influence calcium homeostasis and nonenzymatic antioxidant reserve in erythrocytes of preterm newborns [26].

3. Mg Supplements and Pregnancy Outcome

It is well known that plasma Mg falls in pregnancy because of accumulation of ion in the placenta and fetus. Mg is therefore widely given as a supplement during pregnancy, particularly in cases of preterm labor. There are several reports that oral Mg supplementation in pregnancy is safe and that it has a positive effect on fetal morbidity [27]. Patients in preterm labor have significantly depressed serum Mg levels, while in patients with pre-eclampsia, Mg levels are not significantly different from that of the controls [28]. Mg supplementation was found to decrease the rate of FGR, premature rupture of membranes, and premature delivery in risk pregnancies treated with betamimetics [29]. Oral Mg supplementation given before the 25th week of gestation is associated with a lower frequency of preterm births, a lower frequency of low birth weight, and fewer SGA infants compared with the placebo [30]. Mg intake in 513 women who were near the end of their first trimester of pregnancy was determined from records of food consumption. Mg intake correlated with weight, length, and head circumference at birth as well as length of gestation up to a threshold of around 3,200 g of birth weight [31]. On the other hand, Mg supplements (100 mg/day) taken during the second and third trimesters had no effect on the outcome of the pregnancy. The effect of Mg compared with placebo in a randomized double-blind controlled study of patients with pregnancy-induced hypertension was investigated [32]. Mg supplementation was found to be beneficial in the management of pregnancy-induced hypertension.

At present, there is insufficient high-quality evidence to show that dietary Mg supplementation during pregnancy is beneficial [30]. Any influence of Mg has been confined to the first trimester or earlier. It is important to determine the timing and dose of Mg supplementation as both factors may alter the pregnancy outcome.

4. The Relation of SGA to Intracellular Magnesium in Cord Blood Platelets

We have previously reported that intracellular magnesium ([Mg2+]i) is lower in children with diabetes mellitus and in children who are obese [33]. In the type 2 diabetes mellitus and obese groups, platelets responded well to insulin. Under insulin-resistant states, [Mg2+]i decreases before the poor reactivity to insulin occurs in platelets. From these findings, we hypothesize that [Mg2+]i is decreased earlier than when poor reactivity to insulin develops in platelets exposed to an insulin resistant environment. This suggests that low [Mg2+]i may be an intrinsic abnormality in infants with low birth weight [33]. To test this hypothesis, we studied the relationship of [Mg2+]i in cord blood platelets to birth weight [34]. We found that mean basal [Mg2+]i, but not plasma magnesium, is lower in SGA than in the appropriate for gestational age (AGA) groups (323 ± 162 μmol/L versus 488 ± 132 μmol/L, P = .004 ). Basal [Mg2+]i significantly correlates with birth weight (P < .0001) as well as cord plasma leptin (P = .031) and IGF-1 (P < .001) [35]. [Mg2+]i as well as leptin and IGF-1 reflects the extent of fetal growth. Also, [Mg2+]i significantly correlates with the quantitative insulin sensitivity check index (QUICKI)) (P < .001). Decreased [Mg2+]i in SGA might underlie the initial pathophysiological events that lead to insulin resistance.

Several factors are reported to affect [Mg2+]i. For example, hyperglycemia may have an effect on Mg2+ transport and induce a decline of [Mg2+]i. Barbagallo et al. reported that responses to hyperglycemia in vitro were blunted in adult hypertensive subjects and that these responses were closely linked to basal [Mg2+]i levels [36]. In our study, we found no correlation between cord plasma glucose and basal [Mg2+]i levels. In addition, we did not find any significant difference in plasma glucose levels between the SGA and AGA groups. Intrauterine glucose levels may have less of an effect on inducing SGA or low [Mg2+]i. As [Mg2+]i plays a promotive role in fetal growth, low [Mg2+]i may partly be responsible for SGA.

As low [Mg2+]i is an intrinsic abnormality seen in infants with low birth weight, it is considered that fetal Mg deficiency is an important determinant of insulin resistance in later life [33]. In fact, our data was supported by a recent animal study demonstrating that maternal Mg restriction irreversibly increases body fat and induces insulin resistance in pups by 6 months of age [37].

5. Fetal Programming

The fetal origin hypothesis by Barker et al. [810] states that fetal undernutrition in middle to late gestation leads to disproportionate fetal growth programs and later metabolic diseases. Fetal programming is a phenomenon in which alterations in fetal growth and development in response to the prenatal environment have long-term or permanent effects. This theory was further established in the category of developmental origins of health and disease (DOHaD) [38]. The mechanisms thought to be responsible for fetal programming include the direct effects on cell number, altered stem cell function, and the resetting of regulatory hormonal axes: hypothalamic-pituitary-adrenal axis [39, 40] and growth hormone insulin-like growth factor axis [41]. One of the underlying mechanisms for the postulated early-life programming is that of epigenetics. Altered epigenetic regulation of genes in phenotype induction could possibly give rise to interventions that modify long-term disease risk associated with unbalanced nutrition in early life [42]. Venu et al. reported that fasting insulin and Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) increased in offspring from Mg-restricted dams at 6 months of age [37]. Maternal and postnatal Mg status is important in the long-term programming of body adiposity and insulin secretion in rat offspring [43].

Although low birth weight and poor prenatal nutrition are strongly associated with metabolic syndrome in later life, postnatal catch-up growth was recently considered to also be a pivotal element associated with the development of various pathological conditions [44]. The concept of a sensitive or crucial period that operates to cause long-term changes in development and adverse outcomes later in life is an intriguing one and should be the focus of more studies in the future.

6. Conclusion

Birth weight is only a crude index of early growth and indicates nothing about the success of a fetus in achieving its growth potential. [Mg2+]i may be a marker of early growth restriction, which may be of future diagnostic use as an early predictor of adult diseases. Low [Mg2+]i, which may represent the prenatal programming of insulin resistance, has lifelong effects on metabolic regulation. A biological interpretation of the association between birth size and risk of insulin-resistant diseases should emphasize the possible underlying roles of [Mg2+]i.


Part of this study was supported by the Mami Mizutani foundation and by a Grant-in-Aid for Scientific research (C) from the Japanese Society for the Promotion of Science (no. 21591424). The authors would like to thank the Danone Institute of Japan for its financial support of the 2009 DIJ Research Grant.

AGA: Appropriate for gestational age
FGR: Fatal growth retardation
Mg: Magnesium
[Mg2+]i: Intracellular magnesium
SGA: Small for gestational age.

1. Paolisso G,Scheen A,D’Onofrio FD,Lefebvre P. Magnesium and glucose homeostasisDiabetologiaYear: 19903395115142253826
2. Rosolová H,Mayer O Jr.,Reaven GM. Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrationsMetabolismYear: 200049341842010726923
3. Takaya J,Higashino H,Kobayashi Y. Intracellular magnesium and insulin resistanceMagnesium ResearchYear: 200417212613615319146
4. Resnick LM,Gupta RK,Gruenspan H,Alderman Laragh MHJH. Hypertension and peripheral insulin resistance. Possible mediating role of intracellular free magnesiumAmerican Journal of HypertensionYear: 199035, part 13733792190608
5. Huerta MG,Roemmich JN,Kington ML,et al. Magnesium deficiency is associated with insulin resistance in obese childrenDiabetes CareYear: 20052851175118115855585
6. Nadler JL,Buchanan T,Natarajan R,Antonipillai I,Bergman R,Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesisHypertensionYear: 1993216102410298505087
7. Barker DJP,Hales CN,Fall CHD,Osmond C,Phipps K,Clark PMS. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growthDiabetologiaYear: 199336162678436255
8. Hales CN,Barker DJP. The thrifty phenotype hypothesisBritish Medical BulletinYear: 20016052011809615
9. Lucas A. Programming by early nutrition: an experimental approachJournal of NutritionYear: 19981282, supplement401S406S9478036
10. Kanaka-Gantenbein C. Fetal origins of adult diabetesAnnals of the New York Academy of SciencesYear: 201012059910520840260
11. Barbosa NOE,Okay TS,Leone CR. Magnesium and intrauterine growth restrictionJournal of the American College of NutritionYear: 2005241101515670979
12. Denguezli W,Faleh R,Hajjaji A,et al. Maternal nutrition as a determinant of fetal weight: role of trace elements and vitaminsJournal de Gynecologie Obstetrique et Biologie de la ReproductionYear: 2007365473478
13. Pathak P,Kapoor SK,Kapil U,Dwivedi SN. Serum magnesium level among pregnant women in a rural community of Haryana State, IndiaEuropean Journal of Clinical NutritionYear: 200357111504150614576766
14. Yang CY,Chiu HF,Tsai SS,Chang CC,Sung FC. Magnesium in drinking water and the risk of delivering a child of very low birth weightMagnesium ResearchYear: 2002153-420721312635874
15. Widdowson EM. Davis JA,Dobbing JChanges in body composition during growthScientific Foundations of PaediatricsYear: 1981London, UKWilliam Heinemann330342
16. Husain SM,Mughal MZ. Mineral transport across the placentaArchives of Disease in ChildhoodYear: 19926778748781519992
17. Nandakumaran M,Dashti HM,Surname F. Maternal-fetal transport kinetics of copper, selenium, magnesium and iron in perfused human placental lobule: in vitro studyMolecular and Cellular BiochemistryYear: 20022311-291411952171
18. Standley PR,Standley CA. Identification of a functional Na/Mg exchanger in human trophoblast cellsAmerican Journal of HypertensionYear: 200215656557012074360
19. Elizabeth KE,Krishnan V,Vijayakumar T. Umbilical cord blood nutrients in low birth weight babies in relation to birth weigjt &amp; gestational ageIndian Journal of Medical ResearchYear: 2008128212813319001675
20. Bischof P,Meisser A,Campana A. Paracrine and autocrine regulators of trophoblast invasion—a reviewPlacentaYear: 200021supplement AS55S6010831123
21. Yi FUX,Magness RR,Bird IM. Simultaneous imaging of [Ca2+]1 and intracellular NO production in freshly isolated uterine artery endothelial cells: effects of ovarian cycle and pregnancyAmerican Journal of PhysiologyYear: 20052881R140R14815297265
22. Pearson PJ,Evora PRB,Seccombe JF,Schaff HV. Hypomagnesemia inhibits nitric oxide release from coronary endothelium: protective role of magnesium infusion after cardiac operationsAnnals of Thoracic SurgeryYear: 19986549679729564911
23. Gulaboglu M,Borekci B,Halici Z. Placental tissue iodine level and blood magnesium concentration in pre-eclamptic and normal pregnancyInternational Journal of Gynecology and ObstetricsYear: 200798210010417582415
24. David R,Leitch IM,Read MA,Boura ALA,Walters WAW. Actions of magnesium, nifedipine and clonidine on the fetal vasculature of the human placentaAustralian and New Zealand Journal of Obstetrics and GynaecologyYear: 19963632672718883748
25. Holcberg G,Sapir O,Hallak M,et al. Selective vasodilator effect of magnesium sulfate in human placentaAmerican Journal of Reproductive ImmunologyYear: 200451319219715209387
26. Zylinska L,Gulczynska E,Kozaczuk A. Changes in erythrocyte glutathione and plasma membrane calcium pump in preterm newborns treated antenatally with MgSO4NeonatologyYear: 200894427227818784423
27. Spatling L,Spatling G. Magnesium supplementation in pregnancy. A double-blind studyBritish Journal of Obstetrics and GynaecologyYear: 19889521201253349001
28. Kurzel RB. Serum magnesium levels in pregnancy and preterm laborAmerican Journal of PerinatologyYear: 1991821191272006937
29. Conradt A,Weidinger H,Algayer H. Magnesium therapy decreased the rate of intrauterine fetal retardation, premature rupture of membranes and premature delivery in risk pregnancies treated with betamimeticsMagnesiumYear: 19854120282863425
30. Makrides M,Crowther CA. Magnesium supplementation in pregnancyCochrane Database of Systematic ReviewsYear: 20024 Article ID CD000937..
31. Doyle W,Crawford MA,Wynn AH,Wynn SW. Maternal magnesium intake and pregnancy outcomeMagnesium ResearchYear: 1989232052102640903
32. Rudnicki M,Frolich A,Rasmussen WF,McNair P. The effect of magnesium on maternal blood pressure in pregnancy-induced hypertension. A randomized double-blind placebo-controlled trialActa Obstetricia et Gynecologica ScandinavicaYear: 19917064454501763608
33. Takaya J,Higashino H,Kotera F,Kobayashi Y. Intracellular magnesium of platelets in children with diabetes and obesityMetabolismYear: 200352446847112701060
34. Takaya J,Yamato F,Higashino H,Kobayashi Y. Relationship of intracellular magnesium of cord blood platelets to birth weightMetabolismYear: 200453121544154715562397
35. Takaya J,Yamato F,Higashino H,Kaneko K. Intracellular magnesium and adipokines in umbilical cord plasma and infant birth sizePediatric ResearchYear: 200762670070317957162
36. Barbagallo M,Dominguez LJ,Resnick LM. Magnesium metabolism in hypertension and type 2 diabetes mellitusAmerican Journal of TherapeuticsYear: 200714437538517667214
37. Venu L,Kishore YD,Raghunath M. Maternal and perinatal magnesium restriction predisposes rat pups to insulin resistance and glucose intoleranceJournal of NutritionYear: 200513561353135815930437
38. Swanson JM,Entringer S,Buss C,Wadhwa PD. Developmental origins of health and disease: environmental exposuresSeminars in Reproductive MedicineYear: 200927539140219711249
39. Phillips ID,Simonetta G,Owens JA,Robinson JS,Clarke IJ,McMillen IC. Placental restriction alters the functional development of the pituitary-adrenal axis in the sheep fetus during late gestationPediatric ResearchYear: 19964068618668947963
40. Ozanne SE,Wang CL,Colemen N,Smith GD. Altered muscle insulin sensitinity in the male off spring of protein-malnourished rat damsAmerican Journal of PhysiologyYear: 19962716E1128E11348997235
41. Holt RIG. Fetal programming of the growth hormone-insulin-like growth factor axisTrends in Endocrinology and MetabolismYear: 200213939239712367821
42. Burdge GC,Hanson MA,Slater-Jefferies JOL,Lillycrop KA. Epigenetic regulation of transcription: a mechanism for inducing variations in phenotype (fetal programming) by differences in nutrition during early life?British Journal of NutritionYear: 20079761036104617381976
43. Venu L,Padmavathi IJN,Kishore YD,et al. Long-term effects of maternal magnesium restriction on adiposity and insulin resistance in rat pupsObesityYear: 20081661270127618369337
44. Ross MG,Desai M. Gestational programming: population survival effects of drought and famine during pregnancyAmerican Journal of PhysiologyYear: 20052881R25R3315590994

Article Categories:
  • Review Article

Previous Document:  Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia.
Next Document:  Labour and neonatal outcome in small for gestational age babies delivered beyond 36+0 weeks: a retro...